Document Detail

The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
MedLine Citation:
PMID:  1315383     Owner:  NLM     Status:  MEDLINE    
Peripheral neuropathy is an important and disabling side-effect of cisplatin treatment. A new drug, Org 2766, has been found to prevent this neuropathy up to 1 month after treatment. A group of 18 patients with ovarian cancer, who participated in an earlier randomized study with placebo or Org 2766, together with cisplatin and cyclophophamide, were thereafter prospectively followed up to 2 years after discontinuation of treatment to monitor the development of neurological signs and symptoms and vibration perception threshold (VPT). Exploratory, descriptive data analysis shows that between 1 and 4 months after the last cycle the average sum score for neurological signs and symptoms and VPT had deteriorated compared with 1 month after treatment. Thereafter a gradual but incomplete improvement was seen between 4-12 and 12-24 months after treatment. These changes were seen in all patients regardless of previous treatment with Org 2766 or placebo, but deterioration was less pronounced in patients previously treated with Org 2766. These results suggests that treatment with Org 2766 to prevent a cisplatin-induced neuropathy should possibly be continued up to 4 months after the last cycle of cisplatin.
A Hovestadt; M E van der Burg; H B Verbiest; W L van Putten; C J Vecht
Related Documents :
3655273 - Sucralfate versus cimetidine in reflux esophagitis. a single-blind multicenter study.
2305603 - Ciamexone in endocrine orbitopathy. a randomized double-blind, placebo-controlled study.
338253 - Local treatment of psoriasis with desoxymethasone and betamethasone 17,21-dipropionate:...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of neurology     Volume:  239     ISSN:  0340-5354     ISO Abbreviation:  J. Neurol.     Publication Date:  1992 Mar 
Date Detail:
Created Date:  1992-06-01     Completed Date:  1992-06-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0423161     Medline TA:  J Neurol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  143-6     Citation Subset:  IM    
Department of Neurology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenocorticotropic Hormone / analogs & derivatives*,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma / drug therapy*
Cisplatin / administration & dosage,  adverse effects*
Cyclophosphamide / administration & dosage
Double-Blind Method
Ovarian Neoplasms / drug therapy*
Peptide Fragments / therapeutic use*
Peripheral Nervous System Diseases / chemically induced,  drug therapy*,  prevention & control
Sensory Thresholds
Reg. No./Substance:
0/Peptide Fragments; 15663-27-1/Cisplatin; 50-18-0/Cyclophosphamide; 50913-82-1/Org 2766; 9002-60-2/Adrenocorticotropic Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lymphoma-induced polyradiculopathy in AIDS: two cases.
Next Document:  Sequential quantitative scintigraphy of parotid glands with chronic inflammatory diseases.